EBMT 2022 | Next steps for gene-edited NK cells in the treatment of hematological malignancies
Tobias Bexte
• 16 Mar 2022
Tobias Bexte, University Hospital Frankfurt, Goethe University, Frankfurt, Germany, discusses the future of gene-edited natural killer (NK) cells for the treatment of hematological malignancies. CRIPSR-edited NK cells are currently being evaluated in pre-clinical studies. Whilst this promising technology has the potential to overcome a variety of inhibitory immune checkpoint molecules expressed on NK cells, it is necessary to better understand the impact of CRISPR-based gene editing on the activation status and genomic profile of NK cells before implementing this technique in human patients. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
